摘要
本文根据多个国家(地区)对罕见病和罕用药的界定和制定激励措施进行比较,通过分析罕见病和罕用药的现状来了解这些激励措施对罕用药选定的积极作用,探讨我国制定罕用药相关政策的思路。
Based on the comparison of the deifnitions and the incentive measures for both rare diseases and orphan drugs in several countries and regions, their current situation was analyzed so as to learn the positive effects of these incentive measures on the designation of orphan drugs. Suggestions were proposed to explore the policies on the development of orphan drugs in China.
出处
《上海医药》
CAS
2013年第19期27-31,共5页
Shanghai Medical & Pharmaceutical Journal
关键词
罕见病
罕用药
选定
激励
rare diseases
orphan drugs
designation
incentives
